Another initiative was undertaken in 2020 to improve the capture of narrow therapeutic index (NTI) drugs in DrugBank. As different sources capture this concept differently, we developed an internal definition of ‘NTI’ that includes professional consensus on NTI designation, required therapeutic monitoring and available overdose outcomes. For this review, 425 drugs deemed potentially NTI based on various external sources were reviewed, leading to 254 drugs that fit our internal definition. A set of 24 categories that can participate in interactions was then checked to include all relevant NTI drugs. All remaining interactions, not specifically linked to the NTI status of the drug, were also reviewed and new interactions were added where necessary. These efforts ensure accurate drug–drug interaction information for NTI drugs, whose serum levels must be maintained within a narrow range to avoid unacceptable dose-related toxicity.
